Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection

Journal of Immunology

Volumn 188, Issue 10, 2012, Pages 5177-5188

  Burke, Kelly P ^a   Munshaw, Supriya ^a   Osburn, William O ^a   Levine, Jordana ^a   Liu, Lin ^a   Sidney, John ^b   Sette, Alessandro ^b   Ray, Stuart C ^a   Cox, Andrea L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEPATITIS C VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BAYES THEOREM; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL POPULATION; CONTROLLED STUDY; CROSS REACTION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MOLECULAR RECOGNITION; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRUS STRAIN;

CELL LINE; CELLS, CULTURED; COHORT STUDIES; CONSENSUS SEQUENCE; CROSS REACTIONS; HEPACIVIRUS; HEPATITIS C; HLA ANTIGENS; HUMANS; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; VIRAL HEPATITIS VACCINES;

EID: 84861161553     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103008     Document Type: Article

References (62)

1. Schwartländer, B. 1997. Global burden of disease. Lancet 350: 141-142, author reply 144-145.
2. Alter, M. J., D. Kruszon-Moran, O. V. Nainan, G. M. McQuillan, F. Gao, L. A. Moyer, R. A. Kaslow, and H. S. Margolis. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341: 556-562. (Pubitemid 29384163)
3. Wong, J. B., G. M. McQuillan, J. G. McHutchison, and T. Poynard. 2000. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 90: 1562-1569.
4. Martell, M., J. I. Esteban, J. Quer, J. Genescà, A. Weiner, R. Esteban, J. Guardia, and J. Gómez. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66: 3225-3229.
5. Choo, Q. L., G. Kuo, R. Ralston, A. Weiner, D. Chien, G. Van Nest, J. Han, K. Berger, K. Thudium, C. Kuo, et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 91: 1294-1298. (Pubitemid 24058997)
6. Osburn, W. O., B. E. Fisher, K. A. Dowd, G. Urban, L. Liu, S. C. Ray, D. L. Thomas, and A. L. Cox. 2010. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 138: 315-324.
7. Dowd, K. A., D. M. Netski, X. H. Wang, A. L. Cox, and S. C. Ray. 2009. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136: 2377-2386.
8. Pestka, J. M., M. B. Zeisel, E. Bläser, P. Schürmann, B. Bartosch, F. L. Cosset, A. H. Patel, H. Meisel, J. Baumert, S. Viazov, et al. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104: 6025-6030. (Pubitemid 47175652)
9. Cooper, S., A. L. Erickson, E. J. Adams, J. Kansopon, A. J. Weiner, D. Y. Chien, M. Houghton, P. Parham, and C. M. Walker. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10: 439-449. (Pubitemid 29205480)
10. Grüner, N. H., T. J. Gerlach, M. C. Jung, H. M. Diepolder, C. A. Schirren, W. W. Schraut, R. Hoffmann, R. Zachoval, T. Santantonio, M. Cucchiarini, et al. 2000. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181: 1528-1536. (Pubitemid 30387741)
11. Lechner, F., D. K. Wong, P. R. Dunbar, R. Chapman, R. T. Chung, P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B. D. Walker. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191: 1499-1512. (Pubitemid 30257347)
12. Shoukry, N. H., A. Grakoui, M. Houghton, D. Y. Chien, J. Ghrayeb, K. A. Reimann, and C. M. Walker. 2003. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197: 1645-1655. (Pubitemid 36745340)
13. Day, C. L., G. M. Lauer, G. K. Robbins, B. McGovern, A. G. Wurcel, R. T. Gandhi, R. T. Chung, and B. D. Walker. 2002. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76: 12584-12595. (Pubitemid 35386944)
14. Eckels, D. D., H. Wang, T. H. Bian, N. Tabatabai, and J. C. Gill. 2000. Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol. Rev. 174: 90-97. (Pubitemid 30201381)
15. Rutebemberwa, A., S. C. Ray, J. Astemborski, J. Levine, L. Liu, K. A. Dowd, S. Clute, C. Wang, A. Korman, A. Sette, et al. 2008. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 181: 8215-8225.
16. Kasprowicz, V., J. Schulze Zur Wiesch, T. Kuntzen, B. E. Nolan, S. Longworth, A. Berical, J. Blum, C. McMahon, L. L. Reyor, N. Elias, et al. 2008. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J. Virol. 82: 3154-3160. (Pubitemid 351329205)
17. Radziewicz, H., C. C. Ibegbu, M. L. Fernandez, K. A. Workowski, K. Obideen, M. Wehbi, H. L. Hanson, J. P. Steinberg, D. Masopust, E. J. Wherry, et al. 2007. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81: 2545-2553. (Pubitemid 46447020)
18. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354. (Pubitemid 44435155)
19. Cox, A. L., T. Mosbruger, Q. Mao, Z. Liu, X. H. Wang, H. C. Yang, J. Sidney, A. Sette, D. Pardoll, D. L. Thomas, and S. C. Ray. 2005. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201: 1741-1752. (Pubitemid 41002893)
20. Allen, T. M., M. Altfeld, X. G. Yu, K. M. O'Sullivan, M. Lichterfeld, S. Le Gall, M. John, B. R. Mothe, P. K. Lee, E. T. Kalife, et al. 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78: 7069-7078. (Pubitemid 38781545)
21. Timm, J., G. M. Lauer, D. G. Kavanagh, I. Sheridan, A. Y. Kim, M. Lucas, T. Pillay, K. Ouchi, L. L. Reyor, J. Schulze zur Wiesch, et al. 2004. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 200: 1593-1604.
22. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothé, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407: 386-390.
23. Jones, N. A., X.Wei, D. R. Flower, M.Wong, F. Michor, M. S. Saag, B. H. Hahn, M. A. Nowak, G. M. Shaw, and P. Borrow. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200: 1243-1256. (Pubitemid 39552566)
24. Yokomaku, Y., H. Miura, H. Tomiyama, A. Kawana-Tachikawa, M. Takiguchi, A. Kojima, Y. Nagai, A. Iwamoto, Z. Matsuda, and K. Ariyoshi. 2004. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J. Virol. 78: 1324-1332. (Pubitemid 38095842)
25. Erickson, A. L., Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, J. Sidney, D. McKinney, A. Sette, A. L. Hughes, and C. M. Walker. 2001. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15: 883-895. (Pubitemid 34075370)
26. Houghton, M., and S. Abrignani. 2005. Prospects for a vaccine against the hepatitis C virus. Nature 436: 961-966. (Pubitemid 41191672)
27. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360. (Pubitemid 34734202)
28. McElrath, M. J., and B. F. Haynes. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
29. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153: 5586-5592. (Pubitemid 24377694)
30. Botten, J., J. Alexander, V. Pasquetto, J. Sidney, P. Barrowman, J. Ting, B. Peters, S. Southwood, B. Stewart, M. P. Rodriguez-Carreno, et al. 2006. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. 80: 8351-8361. (Pubitemid 44384848)
31. Kotturi, M. F., I. Scott, T. Wolfe, B. Peters, J. Sidney, H. Cheroutre, M. G. von Herrath, M. J. Buchmeier, H. Grey, and A. Sette. 2008. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J. Immunol. 181: 2124-2133.
32. Loffredo, J. T., J. Sidney, C. Wojewoda, E. Dodds, M. R. Reynolds, G. Napoé, B. R. Mothé, D. H. O'Connor, N. A. Wilson, D. I. Watkins, and A. Sette. 2004. Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J. Immunol. 173: 5064-5076. (Pubitemid 39387789)
33. Corbet, S., H. V. Nielsen, L. Vinner, S. Lauemoller, D. Therrien, S. Tang, G. Kronborg, L. Mathiesen, P. Chaplin, S. Brunak, et al. 2003. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J. Gen. Virol. 84: 2409-2421. (Pubitemid 37063130)
34. Mizukoshi, E., J. Sidney, B. Livingston, M. Ghany, J. H. Hoofnagle, A. Sette, and B. Rehermann. 2004. Cellular immune responses to the hepatitis B virus polymerase. J. Immunol. 173: 5863-5871. (Pubitemid 39392177)
35. Folgori, A., S. Capone, L. Ruggeri, A. Meola, E. Sporeno, B. B. Ercole, M. Pezzanera, R. Tafi, M. Arcuri, E. Fattori, et al. 2006. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12: 190-197. (Pubitemid 43214745)
36. Simmonds, P., J. Bukh, C. Combet, G. Deléage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspé, C. Kuiken, G. Maertens, et al. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973. (Pubitemid 41401136)
37. Neumann-Haefelin, C., D. N. Frick, J. J. Wang, O. G. Pybus, S. Salloum, G. S. Narula, A. Eckart, A. Biezynski, T. Eiermann, P. Klenerman, et al. 2008. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J. Virol. 82: 3438-3451. (Pubitemid 351429920)
38. Bhattacharya, T., M. Daniels, D. Heckerman, B. Foley, N. Frahm, C. Kadie, J. Carlson, K. Yusim, B. McMahon, B. Gaschen, et al. 2007. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315: 1583-1586. (Pubitemid 46449476)
39. Munshaw, S., J. R. Bailey, L. Liu, W. Osburn, K. P. Burke, A. L. Cox, and S. C. Ray. Computational reconstruction of Bole1a, a representative synthetic hepatitis C subtype 1a viral genome. J. Virol. DOI: 10.1128/JVI.05959-11.
40. Cox, A. L., D. M. Netski, T. Mosbruger, S. G. Sherman, S. Strathdee, D. Ompad, D. Vlahov, D. Chien, V. Shyamala, S. C. Ray, and D. L. Thomas. 2005. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin. Infect. Dis. 40: 951-958. (Pubitemid 40418300)
41. Liu, Z., D. M. Netski, Q. Mao, O. Laeyendecker, J. R. Ticehurst, X. H. Wang, D. L. Thomas, and S. C. Ray. 2004. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J. Clin. Microbiol. 42: 4223-4229. (Pubitemid 39296148)
42. Sidney, J., S. Southwood, C. Oseroff, M. F. del Guercio, A. Sette, and H. M. Grey. 2001. Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. Chapter 18: Unit 18.3.
43. Ward, S., G. Lauer, R. Isba, B. Walker, and P. Klenerman. 2002. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin. Exp. Immunol. 128: 195-203. (Pubitemid 34534031)
44. Cox, A. L., T. Mosbruger, G. M. Lauer, D. Pardoll, D. L. Thomas, and S. C. Ray. 2005. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42: 104-112. (Pubitemid 40911317)
45. Wentworth, P. A., A. Sette, E. Celis, J. Sidney, S. Southwood, C. Crimi, S. Stitely, E. Keogh, N. C. Wong, B. Livingston, et al. 1996. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int. Immunol. 8: 651-659. (Pubitemid 26148286)
46. Chang, K. M., N. H. Gruener, S. Southwood, J. Sidney, G. R. Pape, F. V. Chisari, and A. Sette. 1999. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J. Immunol. 162: 1156-1164. (Pubitemid 29035448)
47. Ray, S. C., L. Fanning, X. H. Wang, D. M. Netski, E. Kenny-Walsh, and D. L. Thomas. 2005. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J. Exp. Med. 201: 1753-1759. (Pubitemid 41002894)
48. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88. (Pubitemid 29241119)
49. Assarsson, E., J. Sidney, C. Oseroff, V. Pasquetto, H. H. Bui, N. Frahm, C. Brander, B. Peters, H. Grey, and A. Sette. 2007. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J. Immunol. 178: 7890-7901. (Pubitemid 46898061)
50. Neumann-Haefelin, C., J. Timm, H. C. Spangenberg, N. Wischniowski, N. Nazarova, N. Kersting, M. Roggendorf, T. M. Allen, H. E. Blum, and R. Thimme. 2008. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 47: 1824-1836. (Pubitemid 351945550)
51. Salloum, S., C. Oniangue-Ndza, C. Neumann-Haefelin, L. Hudson, S. Giugliano, M. aus dem Siepen, J. Nattermann, U. Spengler, G. M. Lauer, M. Wiese, et al. 2008. Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J. Virol. 82: 11803-11812.
52. Wölfl,M., A. Rutebemberwa, T.Mosbruger, Q. Mao, H. M. Li, D. Netski, S. C. Ray, D. Pardoll, J. Sidney, A. Sette, et al. 2008. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181: 6435-6446.
53. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
54. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, et al Step Study Protocol Team. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
55. Santra, S., H. X. Liao, R. Zhang, M. Muldoon, S. Watson, W. Fischer, J. Theiler, J. Szinger, H. Balachandran, A. Buzby, et al. 2010. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16: 324-328.
56. Kawashima, Y., K. Pfafferott, J. Frater, P. Matthews, R. Payne, M. Addo, H. Gatanaga, M. Fujiwara, A. Hachiya, H. Koizumi, et al. 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458: 641-645.
57. Yusim, K., W. Fischer, H. Yoon, J. Thurmond, P. W. Fenimore, G. Lauer, B. Korber, and C. Kuiken. 2010. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J. Gen. Virol. 91: 1194-1206.
58. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258. (Pubitemid 351432801)
59. Thimme, R., J. Bukh, H. C. Spangenberg, S. Wieland, J. Pemberton, C. Steiger, S. Govindarajan, R. H. Purcell, and F. V. Chisari. 2002. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 99: 15661-15668. (Pubitemid 35403988)
60. He, X. S., B. Rehermann, F. X. López-Labrador, J. Boisvert, R. Cheung, J. Mumm, H. Wedemeyer, M. Berenguer, T. L. Wright, M. M. Davis, and H. B. Greenberg. 1999. Quantitative analysis of hepatitis C virus-specific CD8 (+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA 96: 5692-5697. (Pubitemid 29234680)
61. Neumann-Haefelin, C., S. McKiernan, S. Ward, S. Viazov, H. C. Spangenberg, T. Killinger, T. F. Baumert, N. Nazarova, I. Sheridan, O. Pybus, et al. 2006. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43: 563-572.
62. Schulze Zur Wiesch, J., D. Ciuffreda, L. Lewis-Ximenez, V. Kasprowicz, B. E. Nolan, H. Streeck, J. Aneja, L. L. Reyor, T. M. Allen, A. W. Lohse, et al. 2012. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J. Exp. Med. 209: 61-75.